Gilead Sciences delivered solid Q4 2025 results with revenue growth and higher net income, supported by strong HIV and Liver Disease product demand despite a significant decline in Veklury sales.

Gilead delivered a solid Q3 2025 with EPS nearly doubling year-over-year, fueled by a sharp drop in impairment charges and a $400M increase in other revenue. Product sales excluding Veklury grew, led by Biktarvy and Livdelzi.

Gilead Sciences delivered a strong second quarter in 2025, with total revenue reaching $7.1 billion, a 2% increase from the previous year. This growth was primarily fueled by robust sales in HIV products, particularly Biktarvy and Descovy, as well as contributions from Livdelzi and Trodelvy. Diluted EPS rose to $1.56, up from $1.29 in Q2 2024, largely due to net unrealized gains on securities and higher product sales, despite an IPR&D impairment charge and increased R&D expenses. The company also increased its full-year revenue and earnings guidance.

Gilead delivered flat total revenue in Q1 2025 with strong performance in HIV therapies, notably Biktarvy, and disciplined cost control contributing to a rebound in profitability after last year’s loss.

Gilead Sciences reported strong Q4 2024 results with total revenue increasing by 6% year-over-year to $7.6 billion, driven by growth in HIV, Oncology, and Liver Disease product sales. EPS increased to $1.42 from $1.14 in Q4 2023, and non-GAAP EPS rose to $1.90. Operating income grew to $2.45 billion, supported by higher product sales and lower costs. Cash and cash equivalents stood at $10.0 billion as of December 31, 2024.

Gilead Sciences announced strong third quarter 2024 financial results, with a 7% increase in total revenue to $7.5 billion. The company is increasing its full-year revenue, operating income, and earnings per share guidance.

Gilead Sciences announced its second quarter 2024 financial results, with total revenue increasing by 5% to $7.0 billion. Product sales, excluding Veklury, grew by 6% year-over-year to $6.7 billion, driven by strong performance in HIV, Oncology, and Liver Disease therapies. The company's EPS increased to $1.29, and non-GAAP EPS reached $2.01.

Gilead Sciences announced its Q1 2024 financial results, revealing a 5% increase in total revenue to $6.7 billion. However, the company reported a diluted loss per share of $(3.34), primarily due to a $3.9 billion acquired IPR&D charge related to the CymaBay acquisition and a $2.4 billion IPR&D impairment. Excluding Veklury, product sales increased by 6% year-over-year. The company's non-GAAP diluted EPS was $(1.32).

Gilead Sciences announced its Q4 2023 financial results, with total revenue decreasing by 4% to $7.1 billion. The decrease was primarily due to lower Veklury and HIV sales, offset by higher Oncology sales. Diluted EPS decreased to $1.14, while non-GAAP diluted EPS increased to $1.72.

Gilead Sciences reported flat total revenue of $7.1 billion for Q3 2023 compared to the same period in 2022. Growth in Oncology and HIV sales was offset by lower Veklury and chronic hepatitis C virus (HCV) product sales. Diluted EPS increased to $1.73, and non-GAAP diluted EPS increased to $2.29.

Gilead Sciences reported a 5% increase in total revenue to $6.6 billion for Q2 2023, driven by growth in HIV and Oncology, which was partially offset by lower Veklury sales and a $525 million litigation accrual. Diluted EPS decreased to $0.83, while non-GAAP diluted EPS decreased to $1.34.

Gilead Sciences reported a 4% decrease in total revenue to $6.4 billion, driven by lower Veklury sales, but experienced growth in HIV and Oncology. Diluted EPS increased to $0.80, while non-GAAP diluted EPS decreased to $1.37. The company maintains a strong cash position with $7.2 billion in cash and cash equivalents.

Gilead Sciences announced its Q4 2022 financial results, with total revenue increasing by 2% to $7.4 billion. The growth was primarily driven by increased sales in Oncology, HIV, and HCV, which was partially offset by lower Veklury sales. Diluted EPS increased to $1.30, and non-GAAP diluted EPS increased to $1.67.

Gilead Sciences announced its third quarter 2022 financial results, with product sales excluding Veklury increasing 11% year-over-year to $6.1 billion. Biktarvy sales increased 22% year-over-year to $2.8 billion, and oncology sales increased 79% year-over-year to $578 million. Total revenue decreased 5% to $7.0 billion compared to the same period in 2021, primarily due to lower Veklury sales.

Gilead Sciences reported a strong second quarter in 2022, with total revenue increasing by 1% to $6.3 billion. Excluding Veklury, product sales grew 7% year-over-year. The company saw continued strong demand for its HIV portfolio and oncology revenues reached an all-time high.

Gilead Sciences announced its Q1 2022 financial results, with revenue increasing by 3% to $6.6 billion. Biktarvy sales increased 18% year-over-year to $2.2 billion, and oncology sales increased 60% year-over-year to $420 million. Diluted EPS decreased to $0.02, while non-GAAP diluted EPS increased 4% to $2.12.

Gilead Sciences reported a 2% decrease in total Q4 2021 revenue to $7.2 billion, impacted by lower Veklury sales, but HIV product sales increased by 7%. Diluted EPS decreased to $0.30, and non-GAAP diluted EPS decreased to $0.69, primarily due to charges related to a legal settlement and the Arcus collaboration opt-in.

Gilead Sciences announced its Q3 2021 financial results, with total revenue of $7.4 billion, a 13% increase compared to the same period in 2020. Biktarvy sales increased 20% year-over-year to a record $2.3 billion, and Veklury sales were $1.9 billion. The company updated its full-year guidance, expecting total product sales between $26.0 billion and $26.3 billion and non-GAAP earnings per share between $7.90 and $8.10.

Gilead Sciences announced a 21% increase in total revenue for the second quarter of 2021, reaching $6.2 billion. This growth was primarily driven by sales of Veklury, Biktarvy, and HCV products. The company's EPS increased to $1.21, and non-GAAP EPS increased 68% to $1.87.

Gilead Sciences reported a strong first quarter in 2021, with total revenue increasing by 16% to $6.4 billion. This growth was primarily driven by sales of Veklury, along with contributions from Cell Therapy products and the U.S. launch of Tecartus. The company also saw growth in its Hepatitis B virus (HBV) segment with Vemlidy.

Gilead Sciences reported a 26% increase in total revenues for Q4 2020, primarily driven by Veklury sales. Non-GAAP diluted EPS increased by 99%, while diluted EPS decreased by 42%. The company provided full year 2021 guidance, including product sales and non-GAAP diluted EPS.

Gilead Sciences reported a 17% increase in total revenues, driven by an 18% increase in product sales. Non-GAAP diluted EPS increased by 29%. The acquisition of Immunomedics was a key highlight of the quarter, expected to contribute to future revenue growth.

Gilead Sciences reported second-quarter revenue of $5.1 billion. GAAP net loss was $(3.3) billion, or $(2.66) per share, which included an acquired in-process research and development (“IPR&D”) charge of $4.5 billion related to Gilead’s acquisition of Forty Seven, Inc. Non-GAAP diluted EPS was $1.11 per share.

Gilead Sciences reported total revenues of $5.5 billion, a 5% increase compared to Q1 2019. Diluted EPS was $1.22, while non-GAAP diluted EPS was $1.68. The company is focused on remdesivir and its ongoing commitments to existing medicines.

Gilead Sciences announced its Q4 and full year 2019 financial results. The total revenues for the fourth quarter of 2019 were $5.9 billion, and the net income was $2.7 billion, or $2.12 per diluted share.